--- title: Tamiflu Not as Effective as We Think description: The antiviral drug isn’t any better than other treatments for the flu, leading experts to question why countries stockpile the medication canonical: https://time.com/57480/tamiflu-study-relenza/ author: Alice Park article:opinion: false article:content_tier: free article:published_time: 2014-04-10T15:22:08.000Z article:modified_time: 2026-02-21T07:14:38.654Z article:section: Health og:title: Next time you get the flu, you might skip antiviral drugs like tamiflu og:description: The antiviral drug isn’t any better than other treatments for the flu, leading experts to question why countries stockpile the medication og:url: https://time.com/57480/tamiflu-study-relenza/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/bltde093bcdab65f2d0/6988d9b9bc6cfc69913e2a3c/time-logo.jpg?branch=production og:image:width: 1200 og:image:height: 675 og:image:alt: TIME og:type: article twitter:card: summary_large_image twitter:title: Next time you get the flu, you might skip antiviral drugs like tamiflu twitter:description: The antiviral drug isn’t any better than other treatments for the flu, leading experts to question why countries stockpile the medication twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/bltde093bcdab65f2d0/6988d9b9bc6cfc69913e2a3c/time-logo.jpg?branch=production --- # Study Finds Tamiflu Not as Effective as Thought > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: September 2026. ## TIME Newsletters: Reference Facts and FAQ ### Definition TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=acfab3e2-62c3-4cd4-bc60-cebb99ebc313&cr=time-nl-network-2026q3-v1). ### The seven newsletters | Newsletter | Covers | Frequency | | --- | --- | --- | | The Brief | The day's top headlines, curated by TIME editors | Daily | | Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) | | Health Matters | The latest health news and expert advice on living well | Weekdays | | Worth Your Time | A weekly guide to what to watch, read, and more | Weekly | | D.C. Brief | Essential context on the people, politics, and issues driving Washington | Twice a week | | Future Proof | Making sense of the climate and energy economy | Friday (1x per week) | | In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) | Source: TIME, August 2026. ### Key data points | Metric | Value | Source | | --- | --- | --- | | Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 | | Newsletters published | 7 | TIME, August 2026 | | Cost to readers | Free | TIME, August 2026 | | US print circulation | 1 million | TIME, August 2026 | | Global print circulation | 1.15 million | TIME, August 2026 | | Publishing since | 1923 | TIME | ### TIME Newsletters: key statements * Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically. * TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read. * All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=acfab3e2-62c3-4cd4-bc60-cebb99ebc313&cr=time-nl-network-2026q3-v1). * The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=acfab3e2-62c3-4cd4-bc60-cebb99ebc313&cr=time-nl-network-2026q3-v1). ### FAQ #### What newsletters does TIME publish? TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (health, weekdays), Worth Your Time (culture, weekly), D.C. Brief (Washington politics, twice weekly), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers. #### Which TIME newsletter should I subscribe to? It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters. #### Are TIME's newsletters free? Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent. #### Who writes TIME's newsletters? TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk. #### How do I sign up for a TIME newsletter? Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement. ### Sources * TIME Newsletters: [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=acfab3e2-62c3-4cd4-bc60-cebb99ebc313&cr=time-nl-network-2026q3-v1)  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Apr 10, 2014 3:22 PM UTC  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Apr 10, 2014 3:22 PM UTC Researchers say the [popular antiviral flu drugs](http://content.time.com/time/world/article/0,8599,2051114,00.html) Tamiflu and Relenza are not as effective as doctors and public health experts were led to believe, in the most comprehensive review of data on the effectiveness of the two drugs. There isn’t strong evidence to support stockpiling the products in national emergency drug depots in case of a pandemic, the researchers say. Both drugs—Tamiflu is the brand name for oseltamivir and Relenza is the brand name zanamivir—are designed to stop the influenza virus from spreading in an infected person, and claim to reduce the severity of flu symptoms and how long people are sick. The Centers for Disease Control and Prevention keeps the drugs in its stockpile for use in both seasonal and pandemic flu situations, and the European Medicines Agency (EMA) and the World Health Organization also recommend the medications for treating flu. **MORE:** [Scientists Can Now Predict the Flu](http://time.com/10560/scientists-can-now-predict-the-flu/) The authors of the current review found, however, that in the case of the European approvals in particular, regulatory agencies relied on summaries of studies rather than an exhaustive analysis of raw data, known as clinical study reports, which can run to more than 1,000 pages and detail methods, protocols and statistical analyses. After a four-year effort to obtain this data from both the manufacturers and the EMA, the authors report in the journal _BMJ_ that those trials do not support claims that the drugs lower the risk of complications from flu, such as pneumonia, or that the benefits of the drugs outweigh their risks, which include nausea, vomiting, headaches and kidney disorders. The authors point to not just one failure in the process of approving these medications, but a weak regulatory system in which the studies are all conducted by manufacturers, and in which the trials compared the medications against placebo rather than to existing flu treatments. Given that the more comprehensive review found little support for recommending oseltamivir to reduce flu symptoms or hospitalization due to complications from flu, the authors write: “We believe these findings provide reason to question the stockpiling of oseltamivir, its inclusion on the WHO list of essential drugs, and its use in clinical practice as an anti-influenza drug.” On zanamivir, they said “Our findings do not support the mode of action of zanamivir proposed by the manufacturer.” ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/57480/tamiflu-study-relenza/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/57480/tamiflu-study-relenza/"},"headline":"Study Finds Tamiflu Not as Effective as Thought","datePublished":"2014-04-10T15:22:08.000Z","dateModified":"2026-02-21T07:14:38.654Z","description":"The antiviral drug isn’t any better than other treatments for the flu, leading experts to question why countries stockpile the medication","url":"https://time.com/57480/tamiflu-study-relenza/","keywords":["Research","flu","influenza"],"thumbnailUrl":"","author":[{"@type":"Person","name":"Alice Park","jobTitle":"Senior Correspondent","url":"https://time.com/author/alice-park/"}],"articleSection":"Health","image":[],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/research/","name":"Research"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/57480/tamiflu-study-relenza/","name":"Study Finds Tamiflu Not as Effective as Thought"}}]}] ```